Alamar Biosciences (NASDAQ:ALMR) Posts Earnings Results

Key Points

• Reported loss: Alamar Biosciences posted a quarterly loss of ($1.74) EPS on $26.04 million in revenue.
• Insider buying: Major shareholder Innovation Fund Illumina II and director Nicholas Naclerio each purchased 235,294 shares at $17.00 (about $4.0M), increasing their holdings to 507,076 shares (an ~86.6% rise).
• Stock action: Shares jumped 5.1% to $24.87 on Friday with volume of 177,151 (below the 352,646 average), within a 52‑week range of $21.50–$27.20.

Alamar Biosciences (NASDAQ:ALMR - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($1.74) earnings per share for the quarter, Zacks reports. The company had revenue of $26.04 million during the quarter.

Alamar Biosciences Stock Up 5.1%

NASDAQ ALMR traded up $1.21 during trading on Friday, hitting $24.87. The company's stock had a trading volume of 177,151 shares, compared to its average volume of 352,646. Alamar Biosciences has a 52 week low of $21.50 and a 52 week high of $27.20.

Insider Buying and Selling at Alamar Biosciences

In related news, major shareholder Innovation Fund Gp Illumina II purchased 235,294 shares of Alamar Biosciences stock in a transaction on Monday, April 20th. The stock was purchased at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the acquisition, the insider directly owned 507,076 shares in the company, valued at approximately $8,620,292. This trade represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nicholas Naclerio purchased 235,294 shares of the firm's stock in a transaction on Monday, April 20th. The stock was bought at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the completion of the transaction, the director directly owned 507,076 shares in the company, valued at approximately $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Alamar Biosciences to a "hold" rating in a research note on Saturday, April 25th.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.